Pregnancy is a very particular moment in a woman’s life during which many functional and metabolic parameters are carefully monitored. Among others, blood glucose, gestational weight gain (GWG), and the risk of gestational diabetes mellitus [GDM and glycated hemoglobin (HbA1c)] are constantly checked to avoid the risk of developing maternal pregnancy-related complications.

These parameters have been taken into consideration by the Danish group of Andreas Munk Petersen in a recent study published in Maternal and Pediatric Nutrition. In this randomized double-blinded placebo-controlled study, 50 obese pregnant women were randomly assigned to the treatment groups to receive 4 capsules containing the De Simone Formulation (Vivomixx®, 450 billion live bacteria per day) or placebo, from gestational week 14–20 until delivery. All visits also included fecal sampling to evaluate the intestinal microbiota. Fecal analysis showed a significant increase in bacterial biodiversity in the group integrated with probiotic, thus demonstrating that Vivomixx® is able to modulate the intestinal microbiota in obese women during pregnancy.

In general, both groups showed neither adverse events nor side effects, confirming the safety of use of this product during pregnancy.

Pr De Simone, About

Halkjaer S et al. Curr Dev Nutr 2020;4:nzaa095.

Share this article!

Categories: DSF, Gynecology, Probiotics

Keep connected, Subscribe


The Letter of Probiotics


The Letter of Probiotics

No spamming, no advertising. Science.

Subscribe to Pr De Simone’s blog. Get his latest analysis on the ever-evolving field of probiotics and their involvement in cutting-edge therapies.